NCT03946670 - A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

April 26, 2022

Study Completion Date

July 15, 2024

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

MBG453

MBG453 is being administered i.v.

DRUG

Placebo

Placebo is being administered i.v.

DRUG

Hypomethylating agents

Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.

Trial Locations (47)

1140

Novartis Investigative Site, Vienna

2930

Novartis Investigative Site, Brasschaat

3000

Novartis Investigative Site, Leuven

4032

Novartis Investigative Site, Debrecen

4400

Novartis Investigative Site, Nyíregyháza

10002

Novartis Investigative Site, Taipei

12808

Novartis Investigative Site, Prague

13353

Novartis Investigative Site, Berlin

20089

Novartis Investigative Site, Rozzano

20162

Novartis Investigative Site, Milan

29010

Novartis Investigative Site, Málaga

31059

Novartis Investigative Site, Toulouse

35100

Novartis Investigative Site, Izmir

39008

Novartis Investigative Site, Santander

41380

Novartis Investigative Site, Kocaeli

50134

Novartis Investigative Site, Florence

55139

Novartis Investigative Site, Samsun

73210

Ohio State Comprehensive Cancer Center James Cancer Hospital, Columbus

75251

Mary Crowley Cancer Research, Dallas

83301

Novartis Investigative Site, Kaohsiung City

89100

Novartis Investigative Site, Reggio Calabria

91010

City of Hope National Medical Center Medical Oncology & Therapeutic, Duarte

06520

Yale University School Of Medicine, New Haven

02215

Dana Farber Cancer Institute, Boston

08901

The Cancer Institute of New Jersey, New Brunswick

M5G 2M9

Novartis Investigative Site, Toronto

G1J 1Z4

Novartis Investigative Site, Québec

625 00

Novartis Investigative Site, Brno Bohunice

04103

Novartis Investigative Site, Leipzig

681 00

Novartis Investigative Site, Alexandroupoli

411 10

Novartis Investigative Site, Larissa

265 00

Novartis Investigative Site, Pátrai

Unknown

Novartis Investigative Site, Hong Kong

00133

Novartis Investigative Site, Roma

812-8582

Novartis Investigative Site, Fukuoka

960 1295

Novartis Investigative Site, Fukushima

500 8513

Novartis Investigative Site, Gifu

259-1193

Novartis Investigative Site, Isehara

860-0008

Novartis Investigative Site, Kumamoto

983 8520

Novartis Investigative Site, Sendai

852-8501

Novartis Investigative Site, Nagasaki

113-8677

Novartis Investigative Site, Bunkyo Ku

545-8586

Novartis Investigative Site, Osaka

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

M20 2BX

Novartis Investigative Site, Manchester